Oppenheimer Reiterates Outperform on Astria Therapeutics, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and maintained a $30 price target.
June 08, 2023 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating on Astria Therapeutics and maintained a $30 price target.
The reiteration of the Outperform rating and maintenance of the $30 price target by Oppenheimer analyst Hartaj Singh indicates a positive outlook for Astria Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100